ACE Report Cover
Sublingual Sufentanil Tablet System vs Peri-Nervous Injection of Ropivacaine for Post-Op Pain
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
ARTHROPLASTY
Sublingual Sufentanil Tablet System vs Peri-Nervous Injection of Ropivacaine for Post-Op Pain .

Sublingual sufentanil tablet system (SSTS) versus a single shot peri-nervous injection of ropivacaine for the management of postoperative pain after total knee arthroplasty: a single-center randomized trial.

Musculoskelet Surg. 2024 01-Sep;():. 10.1007/s12306-024-00833-1

A total of 165 patients undergoing total knee arthroplasty (TKA) were randomized to receive either sublingual sufentanil tablet system (SSTS) (n=84) or a single-shot peri-nervous injection of ropivacaine (n=81). The primary outcome was performance on the Timed Up and Go (TUG) test on the third postoperative day. Secondary outcomes included hospital length of stay, numeric rating scale (NRS) for pain, joint mobility, frequency of rescue analgesic use, side effects, and patient satisfaction. Outcomes were assessed during the hospital stay, typically up to three days postoperatively. Overall, the results revealed that SSTS significantly outperformed ropivacaine in pain control, joint mobility, and recovery metrics, with fewer treatment discontinuations due to uncontrolled pain. These findings suggest that SSTS may provide superior pain management and enable faster recovery in TKA patients.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. Sublingual Sufentanil Tablet System vs Peri-Nervous Injection of Ropivacaine for Post-Op Pain. ACE Report. 2024;306(12):13. Available from: https://myorthoevidence.com/AceReport/Show/sublingual-sufentanil-tablet-system-vs-peri-nervous-injection-of-ropivacaine-for-post-op-pain

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report